研究者詳細 - 依田　尚之

論文 - 依田　尚之

分割表示 113 件中 101 - 113 件目／全件表示 >>

当院での悪性腫瘍手術における希釈式自己血輸血の現状

大平安希子, 原賀順子, 関典子, 依田尚之, 西條昌之, 大道千晶, 西田傑, 小川千加子, 楠本知行, 中村圭一郎, 増山寿

日本産科婦人科学会雑誌 70 ( 2 ) 776 - 776 2018年2月

婦人科悪性腫瘍手術後患者における大建中湯の有用性

藤田志保, 関典子, 西條昌之, 依田尚之, 大道千晶, 原賀順子, 西田傑, 小川千加子, 楠本知行, 鎌田泰彦, 中村圭一郎, 増山寿

日本産科婦人科学会雑誌 70 ( 2 ) 968 - 968 2018年2月

Sarcopenia Is an Important Prognostic Factor in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy. 国際誌

Takanori Kiyotoki, Keiichiro Nakamura, Junko Haraga, Chiaki Omichi, Naoyuki Ida, Masayuki Saijo, Takeshi Nishida, Tomoyuki Kusumoto, Hisashi Masuyama

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 28 ( 1 ) 168 - 175 2018年1月

記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVE: This study aimed to investigate the correlation of sarcopenia findings with prognostic factors in patients with cervical cancer (CC) undergoing concurrent chemoradiotherapy (CCRT). METHODS: We retrospectively collected data on body composition and clinicopathological features from the medical records of 60 patients with CC who underwent CCRT and analyzed correlations between prognosis and changes in body composition as measured by computed tomography (skeletal muscle and iliopsoas muscle [IM]). Statistical analyses were performed using the Mann-Whitney U test. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Cox proportional hazard regression was used for univariate and multivariate analyses. RESULTS: The median follow-up for all patients who were alive at the last follow-up was 33.5 months (range, 1-104 months). The PFS and OS rates were worse for patients with at least 15.0% than for those with less than 15.0% loss of skeletal muscle and IM from baseline (P < 0.001 for both). Furthermore, multivariate analyses showed that at least 15.0% loss of IM was an independent prognostic factor for PFS and OS (P = 0.002 for both). CONCLUSIONS: Sarcopenia (≥15.0% loss of IM from baseline) was revealed to be an important prognostic factor in patients with CC undergoing CCRT.

DOI： 10.1097/IGC.0000000000001127

PubMed

researchmap

The Influence of Adverse Effects on Quality of Life of Survivors of Gynecologic Cancer. 国際誌

Chiaki Omichi, Keiichiro Nakamura, Junko Haraga, Naoyuki Ida, Masayuki Saijo, Takeshi Nishida, Tomoyuki Kusumoto, Hisashi Masuyama

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 27 ( 9 ) 2014 - 2019 2017年11月

記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVE: The objective of this observational study was to investigate correlations between adverse effects (lower-extremity lymphedema [LEL], dysuria, and severe gastrointestinal symptoms) and quality of life (QOL) (physical well-being [PWB], social well-being, emotional well-being [EWB], and functional well-being) before treatment, at least 6 weeks after treatment (posttreatment1), and 3 or 6 months after treatment (posttreatment2) of patients with gynecologic cancer (GC). METHODS: From August 2012 to October 2016, questionnaire responses and clinical data of 75 patients with GC were collected and assessed by treatment received. The χ test was used to determine the significance of correlations. RESULTS: Participants with LEL had significantly poorer QOL than did those without it in the domains of PWB at posttreatment1 (P = 0.026) and EWB at posttreatment2 (P = 0.020). Moreover, patients with 2 adverse effects (LEL plus dysuria or severe gastrointestinal symptoms) had significantly poorer QOL than did those with no or single adverse effect in the domains of PWB at posttreatment1 and posttreatment2 (posttreatment1: P = 0.049, P = 0.001; posttreatment2: P = 0.002, P = 0.028) and poorer QOL compared with those with no adverse effect in the domain of EWB at posttreatment1 (P = 0.017). CONCLUSIONS: Poorer QOL in emotional and physical domains is associated with adverse effects of treatment in patients with GC. It is important to consider the effects of radical therapy not only on survival but also on the QOL of survivors.

DOI： 10.1097/IGC.0000000000001125

PubMed

researchmap

Reply to "Letter to the Editor" by M. Saijo et al. "Glasgow prognostic score is predictive of prognosis for patients with endometrial cancer ". 国際誌

Masayuki Saijo, Keiichiro Nakamura, Hisashi Masuyama, Naoyuki Ida, Tomoko Haruma, Tomoyuki Kusumoto, Noriko Seki, Yuji Hiramatsu

European journal of obstetrics, gynecology, and reproductive biology 216 260 - 260 2017年9月

腹腔鏡下子宮体がん手術単一施設同一術者での経験から

楠本知行, 依田尚之, 西條昌之, 原賀順子, 大道千晶, 西田傑, 小川千加子, 中村圭一郎, 増山寿

日本産科婦人科内視鏡学会雑誌 33 ( Suppl.I ) 352 - 352 2017年8月

Glasgow prognostic score is a prognosis predictor for patients with endometrial cancer. 国際誌

Masayuki Saijo, Keiichiro Nakamura, Hisashi Masuyama, Naoyuki Ida, Tomoko Haruma, Tomoyuki Kusumoto, Noriko Seki, Yuji Hiramatsu

European journal of obstetrics, gynecology, and reproductive biology 210 355 - 359 2017年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVE: This study investigated whether the inflammation-based Glasgow prognostic score (GPS) predicted the prognosis of patients with endometrial cancer (EC) in terms of progression-free survival (PFS) and overall survival (OS). STUDY DESIGN: Pretreatment GPS was examined to determine the correlations with recurrence and survival in 431 patients with EC. Statistical analyses were performed using the Mann-Whitney U test. PFS and OS were analyzed using the Kaplan-Meier method. Cox's proportional hazard regression was used for univariate and multivariate analyses. RESULTS: Median PFS and OS were 49.7 and 52.7 months, respectively. The follow-up range was 1 to 140 months. Kaplan-Meier analysis revealed that patients with EC cancer and high GPS (GPS 2) had a shorter PFS and OS than those with lower GPS (GPS 0+1) (PFS: P<0.001; OS; P<0.001). On multivariate analysis, GPS (GPS 2) was an independent predictor of both recurrence (P<0.001) and survival (P<0.001) for all cases of EC. CONCLUSION: GPS can be useful as an indicator of poor prognosis in patients with EC.

DOI： 10.1016/j.ejogrb.2017.01.024

PubMed

researchmap

Radical Hysterectomy Plus Concurrent Chemoradiation/Radiation Therapy Is Negatively Associated With Return to Work in Patients With Cervical Cancer. 国際誌

Keiichiro Nakamura, Hisashi Masuyama, Naoyuki Ida, Tomoko Haruma, Tomoyuki Kusumoto, Noriko Seki, Yuji Hiramatsu

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 27 ( 1 ) 117 - 122 2017年1月

記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVE: Cervical cancer is one of the most common malignant diseases in working-age women. This study investigated the influence of adverse effects of various treatment modalities on return to work in women with cervical cancer. METHODS: Questionnaires and clinical data from medical records of 97 patients with early stage (stages I and II) cervical cancer were collected and assessed by treatment received. The following treatment groups were analyzed for correlations between time to return to work and various adverse effects: radical hysterectomy (RH) alone, RH group (n = 29); concurrent chemoradiation therapy (CCRT)/radiation therapy (RT) alone, CCRT/RT group (n = 21); and RH + CCRT/RT group (n = 47). The χ test was used to determine the significance of the correlations. RESULTS: The mean age at the time of diagnosis was 43.0 years and the average interval since treatment was 4.5 years. The RH + CCRT/RT group was the most strongly negatively associated with return to work in employed patients who had undergone CCRT/RT group of cervical cancer (P = 0.012). There was a significant association between failure to return to work and lower extremity lymphedema (P = 0.049). A more than-6-month interval between treatment and return to work and reduced personal income occurred in a significantly higher percentage of patients in the RH + CCRT group than in the CCRT/RT group (P = 0.034 and P = 0.034). CONCLUSIONS: Of the treatments assessed, RH + CCRT/RT has the greatest negative effect on return to work in women with cervical cancer.

DOI： 10.1097/IGC.0000000000000840

PubMed

researchmap

Return to work after cancer treatment of gynecologic cancer in Japan. 国際誌

Keiichiro Nakamura, Hisashi Masuyama, Takeshi Nishida, Junko Haraga, Naoyuki Ida, Masayuki Saijo, Tomoko Haruma, Tomoyuki Kusumoto, Noriko Seki, Yuji Hiramatsu

BMC cancer 16 558 - 558 2016年7月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Gynecologic cancer is one of the most common malignant diseases in working-age women. This study investigated whether several characteristics influence return to work after treatment of gynecologic cancer. METHODS: We investigated the correlations between return to work and several other characteristics in 199 gynecologic cancer survivors. Questionnaires were distributed to patients with cancer (≥1 year after treatment and age of <65 years) who visited Okayama University. Logistic regression analysis and receiver operating characteristic curves were used to determine whether each characteristic influenced return to work (no return to work or job change) in these gynecologic cancer survivors. RESULTS: For all patients, the mean age at the time of diagnosis was 47.0 years, and the average number of years after treatment was 4.5. Forty-four patients (53.7 %) who were non-regular employees continued to be employed at the same workplace. Non-regular employment had a significantly higher area under the curve (AUC) (0.726) than other characteristics in terms of negatively affecting return to work. Additionally, non-regular employment tended to have a higher AUC (0.618) than other characteristics in terms of job changes. CONCLUSIONS: Non-regular employment was the variable most likely to negatively affect return to work and job changes in employed patients who underwent treatment for gynecologic cancer.

DOI： 10.1186/s12885-016-2627-0

PubMed

researchmap

Oxidative DNA damage induced by metabolites of chloramphenicol, an antibiotic drug. 国際誌

Shiho Ohnishi, Mariko Murata, Naoyuki Ida, Shinji Oikawa, Shosuke Kawanishi

Free radical research 49 ( 9 ) 1165 - 72 2015年

記述言語：英語掲載種別：研究論文（学術雑誌）

Chloramphenicol (CAP) was an old antimicrobial agent. However, the use of CAP is limited because of its harmful side effects, such as leukemia. The molecular mechanism through which CAP has been strongly correlated with leukemogenesis is still unclear. To elucidate the mechanism of genotoxicity, we examined DNA damage by CAP and its metabolites, nitroso-CAP (CAP-NO), N-hydroxy-CAP (CAP-NHOH), using isolated DNA. CAP-NHOH have the ability of DNA damage including 8-oxo-7,8-dihydro-2'-deoxyguanosine formation in the presence of Cu(II), which was greatly enhanced by the addition of an endogenous reductant NADH. CAP-NO caused DNA damage in the presence of Cu(II), only when reduced by NADH. NADH can non-enzymatically reduce the nitroso form to hydronitroxide radicals, resulting in enhanced generation of reactive oxygen species followed by DNA damage through the redox cycle. Furthermore, we also studied the site specificity of base lesions in DNA treated with piperidine or formamidopyrimidine-DNA glycosylase, using (32)P-5'-end-labeled DNA fragments obtained from the human tumor suppressor gene. CAP metabolites preferentially caused double base lesion, the G and C of the ACG sequence complementary to codon 273 of the p53 gene, in the presence of NADH and Cu(II). Therefore, we conclude that oxidative double base lesion may play a role in carcinogenicity of CAP.

DOI： 10.3109/10715762.2015.1050963

PubMed

researchmap

後腹膜desmoid型線維腫症の症例

西條昌之, 中村圭一郎, 安藤まり, 依田尚之, 岡本和浩, 樫野千明, 谷和祐, 松岡敬典, 春間朋子, 福島千加子, 楠本知行, 関典子, 平松祐司, 佃和憲

現代産婦人科 62 ( 2 ) 263 - 267 2014年4月

記述言語：日本語出版者・発行元：中国四国産科婦人科学会

Desmoid線維腫症は100万人あたり2.4〜4.3例の稀な疾患で、線維腫症の1つであるが、周囲に浸潤性増殖しやすく、根治術を行っても局所再発を繰り返す難治性疾患であることが知られている。症例は22歳、0経妊0経産。4月某日に下腹部痛、軽度の悪心・嘔吐を主訴に近医受診し、巨大骨盤内腫瘤を指摘、精査加療目的に当科を紹介された。MRIでは多房性で一部充実部分を伴った26×24cmの腫瘤を認め、悪性腫瘍も危惧されたため、5月某日に開腹術を施行した。子宮・卵巣は正常であり、腫瘍は後腹膜由来で、回盲部を含め、横行結腸や脾臓下極に浸潤しており、腫瘍摘出とともに横行結腸部分切除吻合、脾臓の部分切除を行った。摘出した腫瘍は2980gで、内容は血性混濁液が存在し、総重量は5kgに達した。病理組織検査にてDesmoid-type fibromatosisと診断され、術後経過は良好で手術後13日目に退院した。後腹膜desmoid線維腫症の1症例を経験したので、若干の文献的考察を加えて報告する。(著者抄録)

researchmap

その他リンク： https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J05038&link_issn=&doc_id=20140620430022&doc_link_id=%2Fcv0mtrob%2F2013%2F006202%2F022%2F0263-0267%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcv0mtrob%2F2013%2F006202%2F022%2F0263-0267%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

子宮頸癌心臓転移の一例

岡本和浩, 楠本知行, 安藤まり, 依田尚之, 樫野千明, 西條昌之, 谷和祐, 春間朋子, 福島千加子, 関典子, 中村圭一郎, 増山寿, 平松祐司

現代産婦人科 62 ( Suppl. ) S46 - S46 2013年9月

当院における羊水染色体検査の現状

依田尚之, 早田桂, 衛藤英理子, 延本悦子, 瀬川友功, 増山寿, 平松祐司

現代産婦人科 62 ( Suppl. ) S38 - S38 2013年9月

　前のページ - 次のページ　

<依田 尚之>

論文 - 依田 尚之

<依田　尚之>

論文 - 依田　尚之